{
    "name": "calcitriol topical",
    "comment": "Rx",
    "other_names": [
        "Vectical"
    ],
    "classes": [
        "Antipsoriatics",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/vectical-calcitriol-topical-345056",
    "pregnancy": {
        "common": [
            "Available data of oral and IV calcitriol use in pregnant females have not identified a drug-associated risk for major birth defects, miscarriages, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Topical administration of calcitriol to pregnant rabbits during organogenesis resulted in an increased incidence of fetal deaths, as well as an increased incidence of minor skeletal abnormalities",
                    "Available data do not allow the calculation of relevant comparisons between the systemic exposures of calcitriol observed in animal studies to the systemic exposures that would be expected in humans after topical use"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available on presence in human milk, effects on breastfed infants, or on milk production",
            "Advise breastfeeding women not to apply ointment directly to nipple and areola to avoid direct infant exposure ",
            "Unknown whether topical administration could result in sufficient systemic absorption to produce detectable quantities in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "In controlled clinical trials hypercalcemia was observed; increased absorption may occur with occlusive dressings; caution if coadministered with medications known to increase serum calcium level (eg, thiazide diuretics, calcium supplements, high-dose vitamin D) "
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid oral",
            "description": {
                "common": "aminolevulinic acid oral, calcitriol topical.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aminolevulinic acid topical",
            "description": {
                "common": "calcitriol topical, aminolevulinic acid topical.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methyl aminolevulinate",
            "description": {
                "common": "calcitriol topical, methyl aminolevulinate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "calcitriol topical, bendroflumethiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "calcitriol topical increases levels of calcium acetate by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcitriol topical increases levels of calcium carbonate by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "calcitriol topical increases levels of calcium chloride by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "calcitriol topical increases levels of calcium citrate by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "calcitriol topical increases levels of calcium gluconate by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "calcitriol topical, chlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "calcitriol topical, chlorthalidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "calcitriol topical, cyclopenthiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "calcitriol topical, hydrochlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "calcitriol topical, indapamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "calcitriol topical, methyclothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "calcitriol topical, metolazone.\nEither increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Potential additive hypercalcemia."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hypercalcemia",
            "percent": "24"
        },
        {
            "name": "Urine abnormality",
            "percent": "4"
        },
        {
            "name": "Psoriasis",
            "percent": "4"
        },
        {
            "name": "Hypercalciuria",
            "percent": "3"
        },
        {
            "name": "Skin discomfort",
            "percent": "3"
        },
        {
            "name": "Pruritus",
            "percent": "1"
        },
        {
            "name": "Acute blistering dermatitis",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Skin burning sensation",
            "percent": null
        }
    ]
}